 |
|
alemtuzumab
A recombinant DNA-derived humanized monoclonal antibody directed against the cell surface glycoprotein, CD52. Alemtuzumab is an IgG1 kappa with human variable framework and constant regions, and complementarity-determining regions derived from a rat monoclonal antibody. This agent selectively binds to CD52, thereby triggering a host immune response that results in lysis of CD52 + cells. CD52 is a glycoprotein expressed on the surface of essentially all normal and malignant B and T cells, a majority of monocytes, macrophages and natural killer (NK) cells, a subpopulation of granulocytes, and tissues of the male reproductive system. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)
| Synonyms: | | anti-CD52 monoclonal antibody
Campath-1H
Monoclonal Antibody Campath-1H
Monoclonal Antibody CD52 | | | | US brand name: | | Campath | | | | Foreign brand name: | | MabCampath | | | | Abbreviation: | | MoAb CD52 | | |
|
|
